SCHEMBL6784658

SCHEMBL6784658

Fc1cc(-c2cccc3c2C2CCNCCC2N3)ccc1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 8/20 0.37
FEN1 P39748 7/20 0.37
HRH1 P35367 1/20 0.36
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
KCNH2 Q12809 2/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
F10 P00742 2/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
CREBBP Q92793 1/20 0.33
HTR1A P08908 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784662 1.00 ALOX5AP (0.37) ALOX5APFEN1HRH1HTR2AHTR2C
SCHEMBL6785254 0.88 CREBBP (0.42) ALOX5APFEN1HTR2AKCNH2LMNA
SCHEMBL6785250 0.88 CREBBP (0.42) ALOX5APFEN1HTR2AKCNH2LMNA
SCHEMBL6791319 0.88 HRH1 (0.42) HRH1HTR2AHTR2CKCNH2LMNA
SCHEMBL6791321 0.88 HRH1 (0.42) HRH1HTR2AHTR2CKCNH2LMNA
SCHEMBL6790777 0.86 BRD4 (0.40) HRH1LMNATSHRCREBBPHTR1A
SCHEMBL6790774 0.86 BRD4 (0.40) HRH1LMNATSHRCREBBPHTR1A
SCHEMBL6782255 0.84 PLAT (0.39) LMNATSHRHTR1ASLC6A2SLC6A4
SCHEMBL6782257 0.84 PLAT (0.39) LMNATSHRHTR1ASLC6A2SLC6A4
SCHEMBL6785602 0.84 HTR7 (0.40) HRH1HTR2AHTR2CKCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828314-B2 Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity PFIZER 2004-12-07 US disclosed
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives PHARMACIA & UPJOHN COMPANY 2003-12-04 US disclosed
US-6586421-B2 For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders PHARMACIA & UPJOHN COMPANY 2003-07-01 US disclosed
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives PHARMACIA & UPJOHN COMPANY 2002-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives HTR5A, HTR1A, HTR4 ALOX5AP 466/4885FEN1 3676/4885HRH1 190/4885
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives HTR5A, HTR1A, HTR4 ALOX5AP 466/4885FEN1 3676/4885HRH1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.